Candel Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $125,000 | $125,000 |
| Operating income | -$48.3M | -$33.4M | -$38.4M | -$34.7M | -$25.7M |
| Operating expenses | $48.3M | $33.4M | $38.4M | $34.8M | $25.9M |
| Cash from operations | -$38.3M | -$27.0M | -$34.2M | -$31.4M | -$22.2M |
| Capital expenditure | $587,000 | $16,000 | $457,000 | $1.3M | $1.8M |
| Free cash flow | -$38.9M | -$27.0M | -$34.7M | -$32.7M | -$24.1M |
| Impairments | $90,000 | $41,000 | $400,000 | — | — |
| Total assets | $125.2M | $106.9M | $41.2M | $77.7M | $89.2M |
| Total liabilities | $73.3M | $40.5M | $28.5M | $30.0M | $25.1M |
| Total debt | $46.1M | $11.6M | $20.5M | — | — |
Shares outstanding 73.3M · Free float 93.0%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.